Lentivector-based immunizations inhibit B16/A2 tumor growth in vivo. HHD mice were inoculated with 3 × 105 B16/A2 cells and immunized 5 days later as indicated (“In vivo tumor protection”). (A) Tumor sizes in each vaccinated group of mice are shown. The numbers in parentheses indicate the number of mice that have tumor recurrence of a total of 10. (B) The mouse survival time was estimated using the Kaplan-Meier method and recorded until 80 days. *Statistically significant survival value between lentivector groups and peptide group (P < .05; log-rank test). (C) HHD mice (n = 6/group) were prior immunized either with pY572/adjuv or with lv-hTERT plus pY572/IFA and subsequently challenged intravenously with 106 B16/A2 cells. Results represent the number of lung metastases counted after 18 days in each mouse, and representative photographs of lung from 1 mouse per group are shown.
